/images/ppid_59c68470-image-176287517293620430.webp)
What is the story about?
JB Chemicals & Pharmaceuticals Ltd on Tuesday (November 11) reported a 19% year-on-year rise in consolidated net profit at ₹207.8 crore for the quarter ended September 30, driven by robust domestic formulations sales and steady international business momentum.
Revenue for the quarter rose 8.4% to ₹1,085 crore from ₹1,000 crore in the corresponding period last year. EBITDA increased 14.4% to ₹309.3 crore, while margins improved to 28.5% from 27% a year earlier, the company said in a filing.
The company’s domestic formulations business, which accounted for over 60% of total revenue, grew 9% YoY to ₹644 crore, led by strong performances from key brands such as Cilacar, Metrogyl, Nicardia, and Sporlac. The Razel franchise crossed ₹100 crore in sales during the quarter, marking a 12% rise, JB Pharma stated.
The international business posted a 7% increase in revenue at ₹441 crore, supported by stable demand in formulations and a 20% growth in the contract development and manufacturing (CDMO) division, backed by a healthy order pipeline. The company also said gross margins improved by 200 basis points at 68.2%, aided by cost optimisation, favourable product mix, and pricing actions.
The shares of JB Pharma ended 0.7% in the green on Tuesday, November 11. The stock of the company has fallen close to 3% in the year so far.
Catch live Q2 updates with CNBC-TV18.com's blog
Revenue for the quarter rose 8.4% to ₹1,085 crore from ₹1,000 crore in the corresponding period last year. EBITDA increased 14.4% to ₹309.3 crore, while margins improved to 28.5% from 27% a year earlier, the company said in a filing.
The company’s domestic formulations business, which accounted for over 60% of total revenue, grew 9% YoY to ₹644 crore, led by strong performances from key brands such as Cilacar, Metrogyl, Nicardia, and Sporlac. The Razel franchise crossed ₹100 crore in sales during the quarter, marking a 12% rise, JB Pharma stated.
The international business posted a 7% increase in revenue at ₹441 crore, supported by stable demand in formulations and a 20% growth in the contract development and manufacturing (CDMO) division, backed by a healthy order pipeline. The company also said gross margins improved by 200 basis points at 68.2%, aided by cost optimisation, favourable product mix, and pricing actions.
The shares of JB Pharma ended 0.7% in the green on Tuesday, November 11. The stock of the company has fallen close to 3% in the year so far.
Catch live Q2 updates with CNBC-TV18.com's blog
/images/ppid_a911dc6a-image-17707256352893847.webp)
/images/ppid_a911dc6a-image-177072563100947154.webp)
/images/ppid_a911dc6a-image-177072553694818011.webp)
